A new blood test that tracks the breakdown of nerve cells in the brain in Alzheimer's disease. It is an innovation that is now being presented by researchers at the University of Gothenburg in Sweden, together with colleagues in Italy, Great Britain and the United States.

In recent years, great progress has been made in the development of blood tests, so-called biomarkers, for screening and monitoring various disease processes in Alzheimer's disease. Partly, it has involved identifying amyloid plaques in the brain (formed by the protein beta-amyloid) via blood samples, and in later research also the formation of neurofibrils, small thread-like protein structures that consist of a modified (phosphorylated) form of the nerve cell protein tau.